Literature DB >> 12732876

Vectors for the treatment of autoimmune disease.

D J Gould1, P Favorov.   

Abstract

Gene therapy has been applied in a variety of experimental models of autoimmunity with some success. In this article, we outline recent developments in gene therapy vectors, discuss advantages and disadvantages of each, and highlight their recent applications in autoimmune models. We also consider progress in vector targeting and components for regulating transgene expression, which will both improve gene therapy safety and empower gene therapy to fullfil its potential as a therapeutic modality. In conclusion, we consider candidate vectors that satisfy requirements for application in the principal therapeutic strategies in which gene therapy will be applied to autoimmune conditions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732876     DOI: 10.1038/sj.gt.3302018

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  10 in total

1.  Packaging HIV- or FIV-based lentivector expression constructs and transduction of VSV-G pseudotyped viral particles.

Authors:  Amy Mendenhall; Jacob Lesnik; Chandreyee Mukherjee; Travis Antes; Ranjita Sengupta
Journal:  J Vis Exp       Date:  2012-04-08       Impact factor: 1.355

2.  Gene therapy, early promises, subsequent problems, and recent breakthroughs.

Authors:  Saeideh Razi Soofiyani; Behzad Baradaran; Farzaneh Lotfipour; Tohid Kazemi; Leila Mohammadnejad
Journal:  Adv Pharm Bull       Date:  2013-08-20

Review 3.  Treatment of human disease by adeno-associated viral gene transfer.

Authors:  Kenneth H Warrington; Roland W Herzog
Journal:  Hum Genet       Date:  2006-04-13       Impact factor: 4.132

4.  Prevention of experimental autoimmune encephalomyelitis in DA rats by grafting primary skin fibroblasts engineered to express transforming growth factor-beta1.

Authors:  T Zargarova; O Kulakova; V Prassolov; T Zharmukhamedova; V Tsyganova; V Turobov; D Ivanov; M Parfenov; M Sudomoina; Y Chernajovsky; O Favorova
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

Review 5.  Long noncoding RNAs and tumorigenesis: genetic associations, molecular mechanisms, and therapeutic strategies.

Authors:  Fan Zhang; Liang Zhang; Caiguo Zhang
Journal:  Tumour Biol       Date:  2015-11-19

6.  Gene therapy for arthritis--where do we stand?

Authors:  Yuti Chernajovsky
Journal:  Arthritis Res Ther       Date:  2005-09-14       Impact factor: 5.156

7.  The effects of N-terminal insertion into VSV-G of an scFv peptide.

Authors:  Hanna Dreja; Marc Piechaczyk
Journal:  Virol J       Date:  2006-09-02       Impact factor: 4.099

8.  Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1.

Authors:  Declan Madsen; Emma R Cantwell; Timothy O'Brien; Patricia A Johnson; Bernard P Mahon
Journal:  J Gen Virol       Date:  2009-07-29       Impact factor: 3.891

9.  Expression Cloning of Recombinant Escherichia coli lacZ Genes Encoding Cytoplasmic and Nuclear β-galactosidase Variants.

Authors:  Homayoun Naderian; Zahra Rezvani; Mohammad Ali Atlasi; Hossein Nikzad; Af de Vries Antoine
Journal:  Iran J Basic Med Sci       Date:  2011-07       Impact factor: 2.699

10.  Inhibition of established collagen-induced arthritis with a tumour necrosis factor-alpha inhibitor expressed from a self-contained doxycycline regulated plasmid.

Authors:  David J Gould; Carly Bright; Yuti Chernajovsky
Journal:  Arthritis Res Ther       Date:  2003-12-22       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.